India’s first prospective study finds molecular testing improved diagnostic clarity in 50% of complex sarcoma cases
Safety was equally impressive. ENV-294 was well tolerated
18-year veteran Saharsh will position the CDMO as a premier global API process development and commercial manufacturing specialist
She brings 20 years of in vivo pharmacology experience across academia and industry, including senior scientific and leadership roles at Orion Pharma and Charles River
The partnership has already launched with five active development programs, with both organizations jointly managing regulatory strategy and documentation under a structured, milestone-gated framework
The milestone moves the company closer to its previously announced $120 million US expansion, with groundbreaking slated for late 2026
SNV4818, the oral drug, is pan-mutant–selective PI3K? inhibitor aimed at treating HR+/HER2- breast cancer and potentially other solid tumors
The initiative will be led by David Baker, 2024 Nobel Prize winner in Chemistry, IPD director, professor of biochemistry, and HHMI Investigator at the University of Washington
The Taipei facility boasts 10 GMP API production lines, with a total reactor volume exceeding 350,000 liters
Subscribe To Our Newsletter & Stay Updated
